Kenji Aoki,1,2 Nicole Chang,2 Quinn Humber,2 Amelie Lopez,2 Dariann Davis,2 Jonathan Phisayavong,3 Albert H. W. Jiang,1,2 Janette Bow-Keola,1,2 Matthew Kao,1 Amir Meghdadi,4 Chris Berka,4 Enrique Carrazana,1 Kore Liow1,2
1 John A. Burns School of Medicine, University of Hawaiʻi, Honolulu, HI
2 Hawaii Pacific Neuroscience Memory Disorders Center and Alzheimer’s Research Unit, Honolulu, HI
3 JABSOM Biostatistics Core Facility, Department of Quantitative Health Sciences, University of Hawaiʻi John A. Burns School of Medicine, Honolulu, HI
4 Advanced Brain Monitoring, Carlsbad, CA
Introduction: Alzheimer’s Disease (AD) is the most common cause of dementia, characterized by irreversible neurodegenerative decline. Early detection is imperative to initiate prompt therapies. Yet, Mild Cognitive Impairment (MCI), a non-specific prodrome that may or may not progress to AD, complicates early detection. Greater characterization of both is essential to distinguish them. Biomarker-based Electrophysiology for Advanced Monitoring (BEAM) combines electroencephalography (EEG) and neurocognitive testing to measure brain activity as measured by event-related potentials (ERPs).
Objective/Methods: This study conducted a propensity-matched, retrospective chart review of 108 patients diagnosed with MCI (n=81) or AD (n=27) and who underwent BEAM to identify unique ERP differences in different activity states between AD and MCI via BEAM.
Results: Inter-group differences in Peak Alpha Frequency and Posterior Dominance of Alpha measurements at resting state between MCI and AD cohorts were statistically significant (p=0.001 and 0.027, respectively). Given Hawaiʻi’s unique geographic and financial healthcare obstacles, BEAM’s non-invasiveness and accessibility can be a complementary AD diagnostic instrument in detecting ERP aberrations, especially in early surveillance.
